Tag: <span>RET alterations</span>

Home / RET alterations
Post

Targeted therapy pralsetinib safely effectively treats lung and thyroid cancers with RET alterations

UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER HOUSTON — Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell...